VIP Dosage: Common Protocol and What Human Studies Used
VIP dosage: no FDA-approved product or established dose exists. Common protocol is 200-400 mcg intranasal daily; here is what studies actually used.
The short version
There is no FDA-approved VIP product and no dose established by any regulator. Clinic and practitioner sources describe a common protocol: an intranasal spray, 50 mcg per spray, alternating nostrils. It starts at 4 sprays a day and sometimes rises to 8 over a two-month course. It is labelled here as common practice, not trial-established. Published human studies gave VIP by intravenous infusion or inhalation for other research questions: vasodilation, headache and lung inflammation.
- The common protocol is an intranasal spray, 50 mcg per spray, 4-8 sprays a day for about two months. It is common practice, not an established dose.
- No regulator has reviewed or approved any human dose of VIP.
- The only study testing VIP for an immune-related use gave it by inhalation for 4 weeks, but its published abstract does not state the microgram dose per treatment.
- Separate studies gave intravenous VIP to measure vasodilation and headache, not as treatment. One states a rate of 8 pmol/kg/min.
- Reconstitution and injection-volume math is a separate question from whether any dose is established. Use the calculator only after you understand that gap.
No FDA-approved VIP product exists, and no regulator or trial has established a dose for the immune-support use VIP is sold for. This page lists what published human studies gave people, by route, dose and duration. For VIP’s physiology and its FDA compounding status, see the main VIP guide.
US legal status - Research use only
VIP has no FDA-approved human product and no dose established by any regulator or clinical guideline for the use it is marketed for. It sits in Category 1 of FDA's 503A compounding-substance nomination list - under evaluation, not approved.
VIP dosage: the common protocol
The protocol most often used is an intranasal spray, 50 mcg per spray, alternating nostrils. It starts at 4 sprays a day (200 mcg) and sometimes rises to 8 sprays a day (400 mcg) over a two-month course. This is common practice, not a trial-established or FDA-approved dose.
Common protocol
What is commonly used, not a dose established in trials. No regulator has set a dose for VIP.
- Dose per administration
- 50 mcg
- How often
- 4-8 sprays a day, split across the day, alternating nostrils
- Route
- Nasal spray or drops
- Cycle length
- 8 weeks
Both sources describe the same intranasal protocol popularized for chronic inflammatory response syndrome: 50 mcg per spray, alternating nostrils, starting at 4 sprays a day (200 mcg) and sometimes increasing to 8 sprays a day (400 mcg) over a two-month course.
VIP doses used in human studies
Prasse 2010 - Prasse A, Zissel G, Lützen N et al. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med. 2010;182(4):540-8., in the references below is the closest published human study to VIP’s marketed immune-support use. It is small, open-label and uncontrolled. The other two studies gave VIP intravenously to healthy volunteers or migraine patients to study blood-vessel and headache effects, not as a treatment.
These are three different research questions, not three attempts at the same protocol. They show that VIP has been given safely to people at a stated rate and duration in each case. They are not a menu to choose from.
What is not established
- No consumer dose of VIP is established. No FDA-approved product exists, so no regulator has reviewed a dose, route or schedule for the immune-support use it is sold for.
- No study above tested repeated, long-term dosing for a chronic condition. The sarcoidosis study ran 4 weeks with no placebo comparison. The intravenous studies were single infusions in healthy or migraine populations.
- No human half-life for VIP is established in a source this page could verify, so no dosing interval can be derived from one.
- The common protocol above is not the trial protocol. It reflects what clinic and practitioner sources describe as typical practice, not a dose any study or regulator has shown to be safe or effective.
Reconstitution and injection volume: use the calculator, not a guess
Turning a target amount into an injection or nebulizer volume depends on a specific vial’s concentration and diluent, which this page cannot know. That arithmetic changes nothing about the fact that no consumer dose is established. The dosage calculator handles concentration and draw-volume math. It does not supply or endorse a dose.
Who should not use VIP
No FDA-reviewed contraindication list exists, because no VIP product has gone through that review. There is no established human safety data on pregnancy, breastfeeding, children, drug interactions, or use alongside a diagnosed cardiovascular condition. VIP is a vasodilator, so anyone with low blood pressure or a condition affecting blood-pressure regulation carries an added, unstudied risk from a research-chemical vial of unverified content.
VIP side effects and risks
VIP’s pharmacology carries a known, mechanism-based risk: enough of it can lower blood pressure and cause flushing or a fast heart rate. The intravenous studies above confirm this directly in people. Beyond that, no FDA-reviewed safety label, adverse-reaction rate or long-term safety study exists for an injected or inhaled research-chemical VIP product. Material sold as “research use only” carries no independently verified purity or concentration.
Related
Where to buy VIP for research
Each vendor is checked against my vendor checklist.
1.BioEdge Research Labs
5 mg vial
- No FDA warning letter found
- Names its testing lab
- Batch COAs published
Common questions
What is the usual VIP dose?
Clinic and practitioner sources describe a common protocol of intranasal VIP, 50 mcg per spray, alternating nostrils. It starts at 4 sprays a day (200 mcg) and sometimes rises to 8 sprays a day (400 mcg) over a two-month course. That is common practice reported outside the trial system. No regulator has approved it and no study has shown it to be safe or effective.
What is the correct dose of VIP?
None is established. No FDA-approved VIP product exists, so no regulator has reviewed a dose, route or schedule for it. Published human studies gave VIP at specific doses for specific research questions, and this page reports them. None is an approved or recommended protocol for the immune-support use VIP is marketed for.
Has VIP been given to people for immune or inflammatory conditions?
Once, in a published study. Researchers gave inhaled, nebulized VIP to 20 people with active sarcoidosis for 4 weeks in an open, uncontrolled phase II study. They reported reduced tumor-necrosis-factor-alpha production and increased regulatory T cells. The published abstract does not give the microgram dose per treatment, and the study had no placebo arm, so it cannot establish an effective dose on its own.
What dose has VIP been given at intravenously?
In studies unrelated to immune support, researchers infused VIP intravenously at 8 picomoles per kilogram per minute in a crossover study of 12 people with migraine without aura. The aim was to study cranial blood-vessel dilation, not to treat. A separate crossover study gave 12 healthy volunteers a 2-hour continuous intravenous infusion of VIP to study headache and vasodilation. That abstract does not state the infusion rate.
How often and for how long has VIP been dosed in humans?
It varies by study, and none is a consumer protocol. The inhaled sarcoidosis study ran for 4 weeks. The intravenous vasodilation and headache studies were single infusions, one at a stated continuous rate and the other for a stated 2 hours. Neither was a repeated-dosing schedule.
How do I work out reconstitution and injection volume?
That is arithmetic about a specific vial and diluent, and it does not change the fact that no consumer dose of VIP is established. The dosage calculator handles concentration and draw-volume math for whatever amount is being discussed. It does not supply or endorse a dose.
Who should not use VIP, and what are the risks?
VIP is a vasodilator, so it carries an expected risk of low blood pressure, flushing and a fast heart rate at doses large enough to act systemically. The intravenous studies on this page confirmed this directly. No FDA-reviewed contraindication list exists because no product has gone through that review. There is no established safety data for pregnancy, breastfeeding, children, or use alongside other medications.
References (3 sources)
Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.
- 1.Prasse A, Zissel G, Lützen N et al. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med. 2010;182(4):540-8.Clinical trialPMID 20442436
- 2.Rahmann A, Wienecke T, Hansen JM et al. Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia. 2008;28(3):226-36.Randomised trialPMID 18254893
- 3.Pellesi L, Al-Karagholi MA, Chaudhry BA et al. Two-hour infusion of vasoactive intestinal polypeptide induces delayed headache and extracranial vasodilation in healthy volunteers. Cephalalgia. 2020;40(11):1212-1223.Randomised trialPMID 32594760